Coinbase Global, Inc. vs Roivant Sciences Ltd. Common Shares — how do they compare? Coinbase Global, Inc. trades at $181.02 (market cap $45.38B), while Roivant Sciences Ltd. Common Shares trades at $34.76 (market cap $24.72B). The key difference: Coinbase Global, Inc. is the larger of the two by market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| COIN | ROIV | |
|---|---|---|
Market Cap | $45.38B | $24.72B |
Volume | 11,013,940 | 6,279,442 |
Sector | Financials | Health |
52-Week High | $387.00 | $41.81 |
52-Week Low | $141.09 | $16.04 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $43.03B | $20.99B |
Signals from Pluang's Aura AI — not financial advice
Coinbase Global (COIN) trades at $181.09, up 1.48% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported $7.18B revenue in 2025 with $1.26B net income, though recent quarterly earnings have missed expectations. Positive developments include CFTC approval for derivatives clearing and expanded partnerships with Citigroup, while analyst consensus remains bullish with a $211.91 price target.
The stock presents growth potential from expanding derivatives business and institutional partnerships, but faces risks from earnings volatility and crypto market exposure. With 55% analyst buy ratings and strong cash flow generation, COIN offers upside to price targets, though investors should monitor execution on profitability goals amid competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →